Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients

Bone Marrow Transplantation

Volumn 36, Issue 8, 2005, Pages 709-713

  de Latour, R Peffault ^a   Asselah, T ^b   Levy V ^c   Scieux, C ^c   Devergie, A ^a   Ribaud, P ^a   Esperou H ^a   Traineau, R ^a   Gluckman, E ^a   Valla, D ^b   Marcellin, P ^b   Socie G ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BEAUJON HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Allogeneic bone marrow transplantation; Antiviral therapy; Hepatitis C

Indexed keywords

ALPHA2A INTERFERON; ERYTHROPOIETIN; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALOPECIA; ANEMIA; APPETITE DISORDER; ARTICLE; BLOOD TOXICITY; CHRONIC HEPATITIS; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; RECIPIENT; SCHOOL CHILD; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; LEUKEMIA; LIVER FUNCTION TESTS; LIVING DONORS; MALE; TRANSPLANTATION, HOMOLOGOUS;

EID: 27244439087     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705120     Document Type: Article

References (20)

1. Strasser SI, Myerson D, Spurgeon CL et al. Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up. Hepatology 1999; 29: 1893-1899.
2. Locasciulli A, Testa M, Valsecchi MG et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: A prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999; 68: 1486-1491.
3. Peffault de Latour R, Levy V, Asselah T et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618-1624.
4. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-965.
6. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
7. Hadziyannis SJ, Sette Jr H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
8. Giardini C, Galimberti M, Lucarelli G et al. Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. Bone Marrow Transplant 1997; 20: 767-772.
9. Maury S, Mary JY, Rabian C et al. Prolonged immune deficiency following allogeneic stem cell transplantation: Risk factors and complications in adult patients. Br J Haematol 2001; 115: 630-641.
10. Bittencourt H, Rocha V, Chevret S et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726-2733.
11. Perez-Olmeda M, Soriano V, Asensi V et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003; 19: 1083-1089.
12. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674.
13. Schirren CA, Zachoval R, Gerlach JT et al. Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. J Hepatol 2003; 39: 397-404.
14. Ljungman P, Andersson J, Aschan J et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis 1996; 23: 167-169.
15. Ljungman P, Gomez-Garcia V, Ferrant A et al. Long-term follow-up of hepatitis C virus-infected patients after stem cell transplantation. Bone Marrow Transplant 2004; 33 (Suppl.): S30 (abstract).
16. Ivantes CA, Amarante H, Ioshii SO, Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 2004; 33: 1181-1185.
17. Marcellin P, Levy S, Edinger S. Therapy of hepatitis C: Patients with normal aminotransferase levels. Hepatology 1997; 26 (3 Suppl. 1): 133S-136S.
18. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
19. Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
20. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. Jama 2004; 292: 2839-2848.